HOME >> BIOLOGY >> NEWS
Other highlights in the July 7 JNCI

Study Evaluates Design of Phase I Trials for Targeted Cancer Drugs

One purpose of a phase I clinical trial of a new cytotoxic drug is to determine the side effects associated with increasing drug dose, i.e., determine the dose that produces the maximum effect at which the toxicity can still be tolerated. New targeted, non-cytotoxic anticancer agents, such as small-molecule kinase inhibitors, pose challenges to this paradigm because they can achieve their maximum effect at levels lower than the maximum tolerated dose.

In a new study, Wendy R. Parulekar, M.D., and Elizabeth A. Eisenhauer, M.D., of Queen's University in Kingston, Ontario, reviewed endpoints used in 60 published phase I studies of targeted, non-cytotoxic anticancer agents. They found that the majority of studies used the traditional endpoint of toxicity to determine the recommended dose for the phase II trials. Nontraditional endpoints, such as measures of molecular drug effects in tumor or surrogate tissue or functional imaging studies, were not routinely incorporated into the study design and rarely formed the primary basis for dose selection.

The authors conclude that although phase I studies of targeted anticancer agents in general continue to use traditional endpoints for selection of the recommended phase II dose, suitable molecular measures of drug effect and the means to incorporate them in the early drug development process are needed to optimize dose selection and drug development strategies.

In an editorial, Edward L. Korn, Ph.D., of the National Cancer Institute, discusses the assumptions and considerations required for choosing an endpoint in a phase I trial of a cytotoxic agent, and the challenges in using nontraditional endpoints for the dose selection of targeted, non-cytotoxic agents.

Contact: Wendy Parulekar, Queen's University, wparulekar@ctg.queensu.ca


Possible T
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
6-Jul-2004


Page: 1 2 3

Related biology news :

1. Other highlights in the September 1 JNCI
2. Other highlights in the August 18 JNCI
3. Other highlights in the August 4 JNCI
4. Other highlights in the June 16 JNCI
5. Other Highlights in the June 2 JNCI
6. Other highlights in the May 19 JNCI
7. Other highlights in the May 5 JNCI
8. Other highlights of the March 17 issue of JNCI
9. Other highlights in the March 3 issue of JNCI
10. Other highlights in the February 18 issue of JNCI
11. Other highlights in the February 4 issue of JNCI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/9/2019)... ... July 09, 2019 , ... Murrieta Genomics, a ... incubator program. The founder and CEO of Tx Genetic, Helen Harrison, has spent ... suffering from epithelial connective tissue disorders. , “We are pleased and excited to ...
(Date:6/25/2019)... ... June 25, 2019 , ... ActX ... raw data, easily available from 23andMe, customers can get access to professionally reviewed ... available for both 23andMe Ancestry and Health + Ancestry customers., With the ActX ...
(Date:6/16/2019)... ... June 14, 2019 , ... Respected periodontist, Dr. ... fifth annual Neodent World Congress. Attended by thousands of dental clinicians from all ... in the world of dentistry. The three-day event featured a team of expert ...
Breaking Biology News(10 mins):
(Date:5/31/2019)... City, California (PRWEB) , ... ... ... allowance of our patent applications from the USPTO providing proprietary interest to ... AND METHOD FOR SLEEP DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP rights ...
(Date:5/22/2019)... ... May 22, 2019 , ... Artemis (formerly Agrilyst), the leading ... A funding round co-led by Astanor Ventures and Talis Capital ... and iSelect Fund . The company has raised $11.75m to date and will ...
(Date:5/14/2019)... TOWNSHIP, N.J. (PRWEB) , ... May 13, 2019 ... ... of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device ... new Heliumleak.com company website. The redesigned website aims to improve LDA’s ability to ...
(Date:5/4/2019)... SÃO PAULO, Brazil (PRWEB) , ... May 03, ... ... the lecture given by the President of the Dakila Pesquisas Association, the scientist ... of the Councilmen 2019, in Brasília (DF). Urandir detailed the results of some ...
Breaking Biology Technology:
Cached News: